Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
04/2003
04/23/2003EP1304323A1 Preventives or remedies for atopic dermatitis
04/23/2003EP1304322A2 Carboxylic acid compound and use thereof
04/23/2003EP1304124A1 Diagnostic agent for diabetes comprising 13C labelled compound
04/23/2003EP1304118A2 Therapeutic uses and formulations for BPI protein products.
04/23/2003EP1304113A1 Isolated stromal cells and methods of using the same
04/23/2003EP1304112A1 Isolated stromal cells and methods of using the same
04/23/2003EP1304110A2 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
04/23/2003EP1304106A1 FREEZE-DRIED PREPARATION OF N- o-(p-PIVALOYLOXYBENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME
04/23/2003EP1304101A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
04/23/2003EP1304047A1 Extracts of cacao bean and cacao bean husk with inhibitory effects on carcinogenesis
04/23/2003EP1303631A2 Biotransformation of biologically active compounds made of various classes of chemical substances by means of laccase and manganese peroxidase enzymes
04/23/2003EP1303620A2 Regulation of human desc1-like serine protease
04/23/2003EP1303607A2 High affinity soluble interleukin-18 receptor
04/23/2003EP1303600A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
04/23/2003EP1303599A2 Methylated nucleotide regulation of upa gene expression
04/23/2003EP1303596A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
04/23/2003EP1303538A2 Ghrelin antagonists
04/23/2003EP1303537A2 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases
04/23/2003EP1303533A2 Chimeric peptide immunogens, their preparation and use
04/23/2003EP1303527A1 Matrix metalloproteinase inhibitors
04/23/2003EP1303522A2 Biologically active macrolides, compositions, and uses thereof
04/23/2003EP1303517A1 Indoloquinazolinones
04/23/2003EP1303515A2 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors
04/23/2003EP1303513A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
04/23/2003EP1303511A1 Oxazolidinone derivatives as antimicrobials
04/23/2003EP1303510A2 Cyclic oxyguanidine pyrazinones as protease inhibitors
04/23/2003EP1303509A1 Beta3 adrenergic agonists
04/23/2003EP1303507A1 Pyrimidine derivatives
04/23/2003EP1303499A1 Tetrazole derivatives
04/23/2003EP1303496A1 Pyrimidine derivatives
04/23/2003EP1303492A2 Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
04/23/2003EP1303490A1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
04/23/2003EP1303488A1 Piperidine compounds for use as ccr-3 inhibitors
04/23/2003EP1303487A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
04/23/2003EP1303486A1 Pyrrolidine derivatives as metalloprotease inhibitors
04/23/2003EP1303485A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme
04/23/2003EP1303477A2 1-amino-alkylcyclohexanes as 5-ht3- and neuronal nicotinicreceptor antagonists
04/23/2003EP1303310A1 USE OF THE INTERFERON RECEPTOR 2c POLYPEPTIDE CHAIN TO ENHANCE THE ANTI-GROWTH EFFECTS OF TYPE I INTERFERONS
04/23/2003EP1303307A2 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
04/23/2003EP1303306A2 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
04/23/2003EP1303305A2 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
04/23/2003EP1303302A2 Use of strains of the parapox ovis virus against organ fibrosis
04/23/2003EP1303301A2 Preventing airway mucus production by administration of egf-r antagonists
04/23/2003EP1303296A1 Composition containing an iron complexing protein and a precursor of nitrogen monoxide metabolism and/or a chemical donor of nitrogen monoxide and uses thereof
04/23/2003EP1303294A2 Method for treating unstable angina pectoris
04/23/2003EP1303293A2 Apo-2l receptor agonist and cpt-11 synergism
04/23/2003EP1303290A1 Small peptides and methods for downregulation of ige
04/23/2003EP1303284A1 Compositions and methods for the treatment of skin damage
04/23/2003EP1303281A1 Methods of treatment
04/23/2003EP1303265A2 Use of cox-2 inhibitors for preventing immunodeficiency
04/23/2003EP1303264A1 Compositions and methods for treating cardiovascular disorders
04/23/2003EP1303262A2 Use of a spla2 inhibitor for the treatment of sepsis
04/23/2003EP1303249A1 Antimycotic nail varnish composition
04/23/2003EP1257537A4 Therapeutic morpholino-substituted compounds
04/23/2003EP1237892B1 Method for producing epinastine hydrochloride in the high-melting crystal modification
04/23/2003EP1235842A4 Rna interference pathway genes as tools for targeted genetic interference
04/23/2003EP1222183B1 Benzopyran derivatives
04/23/2003EP1218378B1 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives
04/23/2003EP1185175B1 Method of increasing the content of flavonoids and phenolic substances in plants
04/23/2003EP1154794B1 Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group
04/23/2003EP1140925B1 (3,4 dihydro-2h-benzo[1,4] oxazinyl-methyl)- 3-(1h-indol-3- yl)-alkyl -amines
04/23/2003EP1133483B1 Il-5 inhibiting 6-azauracil derivatives
04/23/2003EP1121102B1 Liposome-entrapped topoisomerase inhibitors
04/23/2003EP1117681B1 Rho-cocotoxin peptides having selective alpha-1 adrenoceptor activity
04/23/2003EP1107744B1 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia
04/23/2003EP1094807B1 Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies
04/23/2003EP1082314B1 New dipeptidyl peptidase iv effectors
04/23/2003EP1045690B1 Benzenesulfonamide inhibitors of pde-iv and their therapeutic use
04/23/2003EP1035848B1 Substituted alkanohydroxamic acids and method of reducing tnf-alpha levels
04/23/2003EP1028738B1 Use of cytokines and mitogens to inhibit pathological immune responses
04/23/2003EP0977767A4 Aminooxy-modified oligonucleotides
04/23/2003EP0956022B1 Hormonal composition consisting of an oestrogen compound and of a progestational compound
04/23/2003EP0946584B1 Meiosis regulating compounds
04/23/2003EP0937041B1 Use of a pharmaceutically acceptable salt of (3R,2'R)-3-[(Cyclopently-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium for the preparation of a medicament
04/23/2003EP0873134B1 Aqueous prolonged release formulation comprising bovine growth hormone-releasing factor
04/23/2003EP0863762A4 Methods of production and use of liquid formulations of plasma proteins
04/23/2003EP0797443B1 A pharmaceutical composition with improved bio-availability of inositol phosphate
04/23/2003EP0794780B1 Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
04/23/2003EP0672145B1 Interleukin-3 (il-3) multiple mutation polypeptides
04/23/2003EP0612348B1 Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
04/23/2003CN1413213A Azaindoles
04/23/2003CN1413211A Substituted 1,3,4-oxadiazoles and method of producing TNF-alpha levels
04/23/2003CN1413207A 5-membered ring heterocyclic compounds with nitrogen
04/23/2003CN1413206A Non peptide tachykinin receptor antagonists
04/23/2003CN1413197A 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
04/23/2003CN1413192A Substituted indole mannich bases
04/23/2003CN1413190A EP4 receptor selective agonists in treatment of osteoporosis
04/23/2003CN1413181A Novel hydronaphtalene compounds prepared by phodium catalyzed ring opening reaction in presence of phosphine ligand
04/23/2003CN1413117A Drugs, drinks or foods
04/23/2003CN1413113A Method of treating gastrointestinal tract disease using purinergic receptor agonists
04/23/2003CN1413112A Nasal drops containing fused pyridazine derivatives
04/23/2003CN1413109A Substituted acylhydroxamic acids and method of reducing TNF-alpha levels
04/23/2003CN1413104A New (aminopropyl) methylphosphinic acids
04/23/2003CN1412295A Oncolytic microorganism expressing heat shock protein and its application
04/23/2003CN1412197A 17 peptide organic compound and its application
04/23/2003CN1411869A Body-strengthening nutrient sour liquor, preparation method and application
04/23/2003CN1411861A Medicine for curing acute injury of muscle and tendon and its preparation method
04/23/2003CN1411812A Oral medicine preparation with high absorbency
04/23/2003CN1411811A 血液循环改善剂 Blood circulation improving agent
04/23/2003CN1411810A Fatigue-resistant drug composition
1 ... 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 ... 1564